Bringing the fundamentals into focus…
Back to Bio-Rad Laboratories, Inc.
How Bio-Rad Laboratories, Inc. stacks up
BIO · against 166 other Healthcare companies of similar size
Valuation
52/ 100
Below the middle of the pack.
Ranked #85 of 167 · scores higher than 48% of peers
Bars: peers in each 10-point band of the valuation score28 peers with a valuation score of 50–59, including BIO · Click a bar to see the companies
Why valuation scores 52?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 4.5% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 2.1% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 71% of peers. Free cash flow yield: 3.5% vs peer median 0.0%
Metric by metric
Position: dot = BIO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | BIO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 166 reported | 2.1% | 2.5% | 44% | 30% | |
| EBITDA yieldHigher is better · 166 reported | 4.5% | 4.7% | 47% | 50% | |
| Free cash flow yieldHigher is better · 101 reported | 3.5% | 2.3% | 66% | 20% | |
| Book yieldHigher is better · 165 reported | 71.6% | 18.8% | 93% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around BIO| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 5 | 11.6B USD | 94 | 58 | |
| 82 | 13.8B USD | 53 | 54 | |
| 82 | 5.5B USD | 53 | 43 | |
| 82 | 14.6B USD | 53 | 59 | |
| 85 | 49.0B CNY (≈$6.9B) | 52 | 60 | |
| 85 | 10.0B USD | 52 | 43 | |
| 85 | 9.3B AUD (≈$6.1B) | 52 | 55 | |
| 88 | 6.1B CHF (≈$7.0B) | 51 | 58 | |
| 88 | 436.2B INR (≈$5.2B) | 51 | ||
| 88 | 18.5B USD | 51 | 62 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score